

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/621,565	07/21/2000	Miri Seiberg	JBP0510	4999
7590 05/25/2004		EXAMINER		
Audley A Ciamporcero Jr Esq Johnson & Johnson			FUBARA, BLESSING M	
One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003			ART UNIT	PAPER NUMBER
			1615	

DATE MAILED: 05/25/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
Office Action Summary		09/621,565	SEIBERG ET AL.				
		Examiner	Art Unit				
		Blessing M. Fubara	1615				
Period fo	The MAILING DATE of this communication app r Reply	ears on the cover sheet with the c	orrespondence address				
THE M - Exten after S - If the - If NO - Failur Any re	DRTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. sions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period we to reply within the set or extended period for reply will, by statute, eply received by the Office later than three months after the mailing d patent term adjustment. See 37 CFR 1.704(b).	B6(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days fill apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONET.	rely filed s will be considered timely. the mailing date of this communication.				
Status							
1)⊠	Responsive to communication(s) filed on <u>17 Fe</u>	<u>bruary 2004</u> .					
2a)[_	This action is FINAL . 2b)⊠ This action is non-final.						
3) 🗌	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Dispositio	on of Claims						
4)	Claim(s) <u>1-22</u> is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
	6)⊠ Claim(s) <u>1-22</u> is/are rejected.						
7)	Claim(s) is/are objected to.						
8) 🗌 (Claim(s) are subject to restriction and/or	election requirement.					
Application Papers							
	he specification is objected to by the Examiner	,					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
	nder 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
1. Certified copies of the priority documents have been received.							
 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage 							
	application from the International Bureau (PCT Rule 17.2(a)).						
* Se	ee the attached detailed Office action for a list o	` **					
		, , , , , , , , , , , , , , , , , , ,					
Attachment(:	s)						
) Notice	of References Cited (PTO-892)	4) Interview Summary (F					
2)	of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449 or PTO/SB/08)	Paper No(s)/Mail Date 5) Notice of Informal Pate					
	No(s)/Mail Date <u>03/05/04</u> .	6) Other:	(
Patent and Trad	lemask Office						

DETAILED ACTION

Examiner acknowledges receipt of request for extension of time and amendment filed 02/17/04 and IDS filed 03/05/04.

Claims

Claims 23-52 were cancelled on 06 February 2003 in an interview with applicants' attorney. These claims cannot be reintroduced in the application as original withdrawn claims. The cancelled claims may be introduced numbered starting with claim no 53. However, it may be noted that those claims if submitted will be subject to the restriction/election requirement that led to their withdrawal. Therefore, claims 1-22 continue to be examined.

Claim Rejections - 35 USC § 112

The rejection of claim 1 under 35 U.S.C. 112, second paragraph, as being indefinite for 1. failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention is withdrawn in light of the amendment to claim 1.

Claim Rejections - 35 USC § 102

2. Claims 1-3, 6, 7, 9, 16 and 19 remain rejected under 35 U.S.C. 102(e) as being anticipated by Costanzo (US 6,323,219).

Applicants argue that Costanzo does not suggest or describe methods where applicants' composition is used to affect hair and that although Costanzo mentions changes in skin pigmentation due to the application of certain composition to the skin, Costanzo does not state that such a composition has any effect on hair growth.

Art Unit: 1615

3. Applicants' arguments filed 02/17/04 have been fully considered but they are not persuasive.

The instant method involves topical application to the skin a topically active composition that comprises one or more compounds derived from one or more of the botanical families. Since the instant method topically applies a composition and Costanzo topically applies to the skin a composition that reads of the instant composition, it would be inherent that the composition of the prior art affects the skin the same way as the instant composition affects the skin. The effect of the composition is inherent. Thus, although Costanzo does not specifically disclose that the composition has an effect on hair growth, since the instant claim and Costanzo apply the same composition to the skin, the effect on the skin from both compositions would be the same. Secondly, the composition having an effect on hair growth is not a limitation of instant claim 1 and limitations from the specification cannot be read into a claim. The rejection is reiterated below.

Costanzo discloses topically applying pharmaceutical or cosmetic composition in an amount effective to mammalian skin to effect changes in pigmentation (column 10, lines 13-17) and soybean milk or other formulations derived directly from legumes is applied to the mammalian skin (column 9, lines 47-52). Costanzo discloses that extracts from the plant families of leguminosae, solanaceae, gramineae and cucurbitacea contain serine protease inhibitors (column 8, lines 52-57). The teaching of Costanzo meets the limitations of the claims.

Claim Rejections - 35 USC § 103

4. Claims 4, 5, 8, 10-14, 16-18 and 20-22 remain rejected under 35 U.S.C. 103(a) as being unpatentable over Costanzo (US 6,323,219) in view of JP 9059166 A.

Applicants argue that Costanzo does not suggest changes in hair appearance and that although Costanzo applies composition that contains soy, the JP 9059166 reference that discloses the presence of isoflavones in soy teaches away from the methods and compositions of the instant claims

5. Applicants' arguments filed 02/17/04 have been fully considered but they are not persuasive.

As discusses above, Costanzo discloses the instant method and the JP reference is relied upon a teaching that soy contain isoflavones. The rejection is reiterated below.

The teachings of Costanzo is discussed above and Costanzo discloses the method of the instant claims. Regarding claims 4 and 5, there is no showing demonstrating that the amount of the inhibitor provides unusual results. Regarding claims 11-14, 16-18 and 20-22, since the composition of the prior art is applied to the skin, the composition would exhibit the properties of the composition on the skin.

Costanzo does not teach that the composition comprising the plant extracts contains isoflavones. However, JP 9059166 discloses that soybean extract contains isoflavones (English abstract). Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to use the extract of soy bean to apply to the skin in order to effect changes in mammalian hair appearance. One having ordinary skill in the art would have been

Art Unit: 1615

motivated to include isoflavone in the composition of Costanzo with the expectation that the composition produce changes in the mammalian hair appearance.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Blessing M. Fubara whose telephone number is (571) 242-0594. The examiner can normally be reached on 7 a.m. to 3:30 p.m. (Monday to Friday).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K. Page can be reached on (571) 272-0602. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Blessing Fubara Althuran Patent Framing

Patent Examiner

Tech. Center 1600